Search

Background: Information-sharing practices, disposition of oocytes, and embryo management are at the discretion of the individual assisted reproductive technology (ART) program, donors, and recipients. Ideally, these practices and policies should reflect the information and decision-making needs of the people involved. The ART program that was the focus of this study has incorporated pre- and postdonation discussion of oocyte and embryo disposition into the screening and follow-up processes to improve overall satisfaction. To improve programmatic policy, we assessed how these discussions and the informed consent process were reflected in oocyte donors’ legal contracts. Methods: This retrospective chart review (n = 55) was designed to identify and assess discrepancies between donors’ consented preferences and their executed legal agreements with oocyte recipients. Results: Sixty-three percent of donors had legal contracts that were inconsistent with their medical informed consent. Of this group, 58% agreed ...

Aim: Issues surrounding egg donation informed consent have recently been spotlighted due to advances in medical genetics. We sought information on attitudes and desires of donors and recipients to craft a program policy on counseling, disclosures, and re-contacting participants. Methods: Between April 2003 and September 2006 we conducted a questionnaire-based evaluation in our oocyte donor program. Donors pre-donation (n = 265) and those undergoing the process (n = 60), and recipients either ante- or postpartum (n = 57), were asked about their desire to know/disclose obstetric outcomes (Question 1); willingness for contact in the event of a medical emergency (Question 2); and wish to know/disclose a liveborn's medical condition (Question 3). Results: Pre-donation questioning among all donors generally revealed reticence to Question 1 (31% [n = 83]), but were overall amenable with Questions 2 and 3 (83% [n = 220] and 83% [n = 219]). Following the donation process, no differences in Questions 1 and 2 were noted, but fewer donors were amenable with Question 3 (pre-donation 93% [n = 56] versus post-donation 38% [n = 23]; P

Issues surrounding egg donation informed consent have recently been spotlighted due to advances in medical genetics. We sought information on attitudes and desires of donors and recipients to craft a program policy on counseling, disclosures, and re-contacting participants.Between April 2003 and September 2006 we conducted a questionnaire-based evaluation in our oocyte donor program. Donors pre-donation (n=265) and those undergoing the process (n=60), and recipients either ante- or postpartum (n=57), were asked about their desire to know/disclose obstetric outcomes (Question 1); willingness for contact in the event of a medical emergency (Question 2); and wish to know/disclose a liveborn's medical condition (Question 3).Pre-donation questioning among all donors generally revealed reticence to Question 1 (31% [n=83]), but were overall amenable with Questions 2 and 3 (83% [n=220] and 83% [n=219]). Following the donation process, no differences in Questions 1 and 2 were noted, but fewer donors were amenable with Question 3 (pre-donation 93% [n=56] versus post-donation 38% [n=23]; P0.01). Overall, recipients were amenable to all three questions (88% [n=50], 74% [n=42] and 88% [n=50]), with similar responses both ante- and postpartum.All programs participating in gamete donation should establish a comprehensive disclosure policy, including consents that are built upon effective lines of communication between clinical staff and legal counsel assuring that parentage, relinquishment, and re-contact information in donor-recipient agreements are consistent with clinic consent documents and desires of both parties; All decisions must be adequately documented and honored and long-term counseling needs should be addressed.